177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy

This publication has 11 references indexed in Scilit:

• Production logistics of 177Lu for radionuclide therapy
  Applied Radiation and Isotopes, 2003
• Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells
  Nuclear Medicine and Biology, 2003
• Preparation and animal biodistribution of ¹⁶⁶Ho labeled DOTA for possible use in intravascular radiation therapy (IVRT)
  Journal of Labelled Compounds and Radiopharmaceuticals, 2003
• Radiolabeled peptides in the diagnosis and therapy of oncological diseases
  Applied Radiation and Isotopes, 2002
• Bifunctional Chelators for Therapeutic Lanthanide Radiopharmaceuticals
  Bioconjugate Chemistry, 2000
• DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and Therapy
  Endocrinology, 1999
• In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT
  European Journal of Nuclear Medicine and Molecular Imaging, 1996
• 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract
  Nuclear Medicine and Biology, 1996
• Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors
  New England Journal of Medicine, 1994
• Somatostatin-Receptor Imaging in the Localization of Endocrine Tumors
  New England Journal of Medicine, 1990